Search Within

Taha Merghoub

  1. "Genitourinary Oncology Service"
Formats
  1. Journal Article (19)
  2. Meeting Abstract (13)
Groups
  1. Department of Medicine (32)
  2. Genitourinary Oncology Service (32)
  3. Melanoma and Immunotherapeutics Service (32)
  4. Solid Tumor Oncology Division (32)
  5. GSK Faculty (29)
  6. Department of Pathology and Laboratory Medicine (18)

More Groups

People
  1. Jedd Wolchok (16)
  2. David Solit (14)
  3. Michael Berger (8)
  4. Samuel Funt (8)
  5. Dean Bajorin (7)
  6. Gopakumar Iyer (7)

More People

Years
  1. 2024 (1)
  2. 2023 (3)
  3. 2022 (5)
  4. 2021 (3)
  5. 2020 (7)
  6. 2019 (1)

More Years

Publications
  1. Journal of Clinical Oncology (10)
  2. Cancer Research (4)
  3. Nature (3)
  4. Clinical Cancer Research (2)
  5. Nature Communications (2)
  6. Cancer Cell (1)

More Publications

Publishers
  1. American Society of Clinical Oncology (11)
  2. American Association for Cancer Research (7)
  3. Nature Publishing Group (6)
  4. American Association for the Advancement of Science (1)
  5. Biomed Central Ltd (1)
  6. Cell Press (1)

More Publishers

Results (32)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Lysis-independent potentiation of immune checkpoint blockade by oncolytic virus
    Journal Article

    Oseledchyk, A.; Ricca, J. M.; Gigoux, M.; Ko, B.; Redelman-Sidi, G.; Walther, T.; Liu, C.; Iyer, G.; Merghoub, T.; Wolchok, J. D.; more...
    Oncotarget (2018)

    Fulltext@MSK | Save
  • Genomic features of response to combination immunotherapy in patients with advanced non-small-cell lung cancer
    Journal Article

    Hellmann, M. D.; Nathanson, T.; Rizvi, H.; Creelan, B. C.; Sanchez-Vega, F.; Ahuja, A.; Ni, A.; Novik, J. B.; Mangarin, L. M. B.; Abu-Akeel, M.; more...
    Cancer Cell (2018)

    Fulltext@MSK | Save
  • Molecular determinants of response to anti-programmed cell death (PD)-1 and anti-programmed death-ligand 1 (PD-L1) blockade in patients with non-small-cell lung cancer profiled with targeted next-generation sequencing
    Journal Article

    Rizvi, H.; Sanchez-Vega, F.; La, K.; Chatila, W.; Jonsson, P.; Halpenny, D.; Plodkowski, A.; Long, N.; Sauter, J. L.; Rekhtman, N.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • PTEN loss-of-function alterations are associated with intrinsic resistance to BRAF inhibitors in metastatic melanoma
    Journal Article

    Catalanotti, F.; Cheng, D. T.; Shoushtari, A. N.; Johnson, D. B.; Panageas, K. S.; Momtaz, P.; Higham, C.; Won, H. H.; Harding, J. J.; Merghoub, T.; more...
    JCO Precision Oncology (2017)

    Fulltext@MSK | Save
  • Contribution of systemic and somatic factors to clinical response and resistance to PD-L1 blockade in urothelial cancer: An exploratory multi-omic analysis
    Journal Article

    Snyder, A.; Nathanson, T.; Funt, S. A.; Ahuja, A.; Buros Novik, J.; Hellmann, M. D.; Chang, E.; Aksoy, B. A.; Al-Ahmadie, H.; Yusko, E.; more...
    PLos Medicine (2017)

    Fulltext@MSK | Save
  • Alternative transcription initiation leads to expression of a novel ALK isoform in cancer
    Journal Article

    Wiesner, T.; Lee, W.; Obenauf, A. C.; Ran, L.; Murali, R.; Zhang, Q.; Wong, E. W. P.; Hu, W.; Scott, S. N.; Shah, R. H.; more...
    Nature (2015)

    Fulltext@MSK | Save
  • A retrospective evaluation of vemurafenib as treatment for BRAF-mutant melanoma brain metastases
    Journal Article

    Harding, J. J.; Catalanotti, F.; Munhoz, R. R.; Cheng, D. T.; Yaqubie, A.; Kelly, N.; McDermott, G. C.; Kersellius, R.; Merghoub, T.; Lacouture, M. E.; more...
    The Oncologist (2015)

    Fulltext@MSK | Save
  • Loss of NF1 in cutaneous melanoma is associated with RAS activation and MEK dependence
    Journal Article

    Nissan, M. H.; Pratilas, C. A.; Jones, A. M.; Ramirez, R.; Won, H.; Liu, C.; Tiwari, S.; Kong, L.; Hanrahan, A. J.; Yao, Z.; more...
    Cancer Research (2014)

    Fulltext@MSK | Save
  • Efficacy of intermittent combined RAF and MEK inhibition in a patient with concurrent BRAF- and NRAS-mutant malignancies
    Journal Article

    Abdel-Wahab, O.; Klimek, V. M.; Gaskell, A. A.; Viale, A.; Cheng, D.; Kim, E.; Rampal, R.; Bluth, M.; Harding, J. J.; Callahan, M. K.; more...
    Cancer Discovery (2014)

    Fulltext@MSK | Save
  • Vemurafenib (VEM) in patients (pts) with BRAF-mutant melanoma and brain metastases (mets)
    Meeting Abstract

    Harding, J. J.; Catalanotti, F.; Yaqubie, A.; McDermott, G. C.; Kersellius, R.; Merghoub, T.; Carvajal, R. D.; D'Angelo, S. P.; Dickson, M. A.; Schwartz, G. K.; more...
    Journal of Clinical Oncology (2013)

    Fulltext@MSK | Save